[Application of pharmacologic treatment in acute myocardial infarction].
Pharmacological therapeutics in acute myocardial infarction. The acute myocardial infarct is one of the main causes of death among the adult population of the industrialized countries, and this pattern is starting to be paralleled in many developing countries. The mortality rate due to coronary diseases has decreased 30% in the last decade, thanks to the new therapeutic strategies and the guidelines developed by the American college of Cardiology and the American Heart Association, aimed at physicians, nurses, and health personnel in charge of patients with suspected myocardial infarct or with an established myocardial infarct. These guidelines and strategies explain the fundaments of the administration of thrombolytic agents, coronary angioplasty, surgery, and the use of betablockers, platelet antiaggregating agents and angiotensin-converting enzyme inhibitors. These recommendations are followed at the Coronary Intensive Care Unit of the National Institute of Cardiology "Ignacio Chávez", and therefore it was necessary to perform this bibliographic review to continue with the safety standards established for the follow-up protocols of the ischemic patient, aimed at assessing their efficacy and efficiency.
Torres Peláez
M L
ML
Unidad Coronaria del Instituto Nacional de Cardiología Ignacio Chávez, INCICH, Juan Badiano No. 1, 14080 México, D.F.
D015906:Angioplasty, Balloon, Coronary; D003131:Combined Modality Therapy; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy*; D009204:Myocardial Revascularization; D015912:Thrombolytic Therapy